DCM
AKTX

DAFNA Capital Management’s Akari Therapeutics AKTX Stock Holding History

DAFNA Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$6K – 81
2016
Q2 		$6K Sell
1
-5
-83% -$64.5K ﹤0.01% 92
2016
Q1 		$66K Sell
6
-4
-40% -$41.5K 0.06% 87
2015
Q4 		$121K Sell
10
-23
-70% -$342K 0.11% 71
2015
Q3 		$633K Buy
+33
New +$390K 0.63% 42
2015
Q1 		– Sell
-5
Closed -$211K – 71
2014
Q4 		$211K Hold
5
– – 0.17% 57
2014
Q3 		$268K Hold
5
– – 0.27% 47
2014
Q2 		$272K Hold
5
– – 0.26% 41
2014
Q1 		$285K Buy
+5
New +$283K 0.25% 40

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DAFNA Capital Management's AKTX Position: Q3 2016 in Review

DAFNA Capital Management sold out of Akari Therapeutics (AKTX) in Q3 2016, closing a stake of 1 share — an estimated $6K sold.

DAFNA Capital Management first reported a position in AKTX in Q1 2014 and held it in 8 quarters. The position peaked at $633K in Q3 2015. 17 funds tracked by Wall St. Rank hold AKTX as of Q3 2016.

  • DAFNA Capital Management reported no remaining Akari Therapeutics position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 1 Akari Therapeutics share in Q3 2016, an estimated $6K.
  • DAFNA Capital Management first reported a position in Akari Therapeutics in Q1 2014 and held it in 8 quarters.
  • DAFNA Capital Management's Akari Therapeutics position peaked at $633K in Q3 2015.
  • 17 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.